SCHEMBL20786522

SCHEMBL20786522

Nc1ncnc2c1ncn2[C@H]1CC[C@@H](COP(O)O)O1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 1/20 0.52
▸ ADA P00813 1/20 0.52
▸ PI4KA P42356 4/20 0.51
▸ PI4K2B Q8TCG2 4/20 0.51
▸ PI4K2A Q9BTU6 4/20 0.51
▸ PI4KB Q9UBF8 4/20 0.51
▸ MAPK1 P28482 2/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ TP53 P04637 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ NFKB1 P19838 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ APEX1 P27695 1/20 0.51
▸ BLM P54132 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ ADCY1 Q08828 1/20 0.51
▸ ADORA2A P29274 4/20 0.49
▸ AHCY P23526 3/20 0.48
▸ PRMT5 O14744 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20927100 1.00 BCHE (0.52) BCHEADAPI4KAPI4K2BPI4K2A
SCHEMBL20785732 0.91 BCHE (0.51) BCHEADAPI4KAPI4K2BPI4K2A
SCHEMBL20792377 0.91 BCHE (0.51) BCHEADAPI4KAPI4K2BPI4K2A
SCHEMBL21540010 0.90 ADA (0.52) BCHEADAPI4KAPI4K2BPI4K2A
SCHEMBL20782393 0.89 BCHE (0.51) BCHEADAPI4KAPI4K2BPI4K2A
SCHEMBL20927155 0.89 BCHE (0.51) BCHEADAPI4KAPI4K2BPI4K2A
SCHEMBL22351987 0.89 BCHE (0.51) BCHEADAPI4KAPI4K2BPI4K2A
SCHEMBL10427715 0.86 BCHE (0.55) BCHEADAPI4KAPI4K2BPI4K2A
SCHEMBL20927136 0.85 BCHE (0.51) BCHEADAPI4KAPI4K2BPI4K2A
SCHEMBL23516968 0.85 BCHE (0.57) BCHEADAPI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661604-B2 Methods and compositions for inhibiting expression of LDHA DICERNA PHARMACEUTICALS, INC. (US) 2023-05-30 — — US disclosed
US-20210062199-A1 METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA NOVO NORDISK HEALTH CARE AG (CH) 2021-03-04 — — US disclosed
WO-2019046496-A1 CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2019-03-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210062199-A1 METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA LDHA, LDHB, GLS2 BCHE 1453/4885ADA 198/4885PI4KA 2964/4885
US-11661604-B2 Methods and compositions for inhibiting expression of LDHA LDHA, LDHB, GLS2 BCHE 1453/4885ADA 198/4885PI4KA 2964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback